News
An innovator in developing therapeutic antibodies, fusion proteins and circRNA
News
2025-08-06
Fapon Biopharma Announces the Enrollment of the First Patient in the Phase I Clinical Trial of FP008, A First-in-Class Immunotherapy for Solid Tumors
Fapon Biopharma is delighted to announce the completion of the first patient enrollment in China for its Phase I clinical trial of FP008 , a first-in-class immunotherapy for solid tumors, at Zhejiang Cancer Hospital.
Read more 
2025-06-11
Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025
Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation in the BIO International Convention 2025 (BIO 2025), taking place June 16-19 in Boston Convention & Exhibition Center.
Read more
2025-02-28
Fapon Biopharma Announces FDA Approval of IND for FP008, a First-in-Class Immunotherapy for Solid Tumors
Read more
2025-01-07
Fapon Biopharma Introduces FP008 at Biotech Showcase: A Safer and More Effective Immunotherapy for Refractory Cancers
Read more
2024-06-04
Fapon Biopharma Announces a Safer Immunotherapy for Cancers
At Bio International Convention 2024, which is taking place here in San Diego during June 3-6, Fapon Biopharma, an innovator in developing therapeutic antibodies and fusion proteins, has announced an immunocytokine with modified IL-10M fused to anti-PD-1 antibody, codenamed FP008.
Read more
2024-03-25
Fapon and Stanford Healthcare Innovation Lab Co-Host Virtual Conference on RNA Delivery and Gene Editing Featuring Nobel Prize Winner
On March 20, the groundbreaking virtual conference "In Vivo Frontiers: The Promise and Progress of RNA Delivery & Gene Editing," hosted by the Stanford Healthcare Innovation Lab in collaboration with Fapon, took place successfully. Distinguished speakers, including Nobel Prize Winner Jennifer Doudna and renowned scientist Robert Langer, alongside other leading experts, presented in the event.
Read more
